List view / Grid view


Filter the results



EC approves Ipsen’s cabometyx to treat advanced RCC following VEGF-targeted therapy

16 September 2016 | By Niamh Louise Marriott,

The European Commission has approved Ibsen’s cabometyx (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx (cabozantinib) demonstrated significant clinical benefits across all three efficacy endpoints (OS, PFS, ORR) in a phase 3…